Methamphetamine psychosis in Australia, Philippines, and Thailand: Recommendations for acute care and clinical inpatient management

Addictive Disorders and their Treatment

Volumn 9, Issue 4, 2010, Pages 143-149

  Ali, Robert ^a   Marsden, John ^b   Srisurapanont, Manit ^c   Sunga, Agueda ^d   Baigent, Michael ^a   Monteiro, Maristela ^e  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d DEPARTMENT OF HEALTH   (Philippines)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Inpatient treatment; Methamphetamine; Psychosis; Substance use disorder

Indexed keywords

METHAMPHETAMINE;

ADOLESCENT; ADULT; ARTICLE; AUDITORY HALLUCINATION; AUSTRALIA; EMERGENCY CARE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; NEGATIVE SYNDROME; PATIENT CARE; PERSECUTORY DELUSION; PHILIPPINES; POSITIVE SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHIATRIC TREATMENT; PSYCHOSIS; SEX RATIO; SPEECH DISORDER; THAILAND; TREATMENT DURATION; VISUAL HALLUCINATION;

EID: 78651399994     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0b013e3181cf58f2     Document Type: Article

References (26)

1. United Nations Office on Drugs and Crime: 2007 World Drug Report. United Nations Office on Drugs and Crime 2007, Vienna.
2. Sulzer D, Sonders M, Poulsen N, et al. Mechanisms of neurotransmitter release by amphetamines:a review. Prog Neurobiol. 2005;75:406-433.
3. Martin W, Sloan J, Sapira J, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-258.
4. Kaye S, McKetin R, Duflou J, et al. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102:1204-1211.
5. Darke S, Kaye S, McKetin R, et al. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008;27:253-262.
6. Ellinwood E. Amphetamine psychosis I. Description of the individuals and the process. J Ner Ment Dis. 1968;144:273-283.
7. Angrist B, Gershon S. The phenomenology of experimentally induced amphetamine psychosis. Biol Psychiatry. 1970;2:95-107.
8. Yui K, Ikemoto S, Ishiguro T, et al. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Annals of the New York Academy of Sciences. 2000;914:1-12.
9. Wada K, Fukui S. Residual symptoms in methamphetamine psychosis. J Ment Health. 1991;37:161-168.
10. Chen C, Lin S, Sham P, et al. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. American Journal of Medical Genetics, Part B Neuropsychiatric Genetics. 2005;136:87-91.
11. Salo R, Nordahl T, Leamon M, et al. Preliminary evidence of behavioral predictors of recurrent druginduced psychosis in methamphetamine abuse. Psychiatry Res. 2008;157:273-277.
12. Farrell M, Marsden J, Ali R, et al. Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction. 2002;97:771-772.
13. Australian Institute of Health and Welfare: 2007 National Drug Strategy Household Survey: first results. Drug Statistics Series Number 20. Cat. no. PHE 98. Canberra: AIHW 2008.
14. Marsden J, Gossop M, Stewart D, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93:1857-1867.
15. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychological Association; 1994.
16. Sheehan D, Lecrubier Y, Sheehan K, et al. The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
17. Lecrubier Y, Sheehan D, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. European Psychiatry. 1997;12:224-231. (Pubitemid 27298915)
18. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica. 1997;55:299-308.
19. Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. International Journal of Neuropsychopharmacology. 2003;6:347-352.
20. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. Journal Medical Association Thailand. 2005;3(88 supplement): S43-S52.
21. McIntyre R, Jerrell M. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives of Pediatrics and Adolescent Medicine. 2008;162:929-935.
22. McIver C, McGregor C, Baigent M, et al. Guidelines for the medical management of patients with methamphetamine-induced psychosis. Drug and Alcohol Services South Australia. 2006.
23. Davis J, Chen N, Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Archives General Psychiatry. 2003;60:553-564.
24. San L, Arranz B, Martinez-Raga J. Antipsychotic Drug Treatment of Schizophrenic Patients with Substance Abuse Disorders. Eur Addict Res. 2007;13:230-243.
25. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Annals of the New York Academy of Sciences. 2004;1025:279-287.
26. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophrenia Bulletin. 1992;18:115-122.